Research Fellow and Clinical Haematologist
I am a Research Fellow and Clinical Haematologist with a specialist interest in Myelodysplastic syndromes and Acute Myeloid Leukaemia (AML). These are oligoclonal myeloid malignancies where genetically distinct clones can result in differences in leukaemia cell function within individual patients. I am investigating how clonal heterogeneity affects the biology of leukaemia stem cells in MDS and AML, in particular response to novel anti-leukaemic therapies. I am integrating genomic and functional approaches, including single cell techniques to elucidate clonal structures, epigenetic and transcriptional heterogeneity. My research and clinical interest converge on the common goal to develop better therapies to MDS and AML patients.
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
Haase D. et al, (2019), Leukemia
Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis
Dillon R. et al, (2018), BLOOD, 132
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Quek L. et al, (2018), Nat Med, 24, 1167 - 1177
Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells.
Karamitros D. et al, (2018), Nat Immunol, 19, 85 - 97
Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia
Quek L. et al, (2017), BLOOD, 130